BUSINESSWEEK ONLINE : JANUARY 29, 2001 ISSUE
INTERNATIONAL -- EUROPEAN BUSINESS Hot Water for Bryntsalov The tycoon and his company face complaints on diverse fronts: MEDICINE QUALITY Some patients hospitalized after taking Bryntsalov insulin. TRADEMARKS Russian Antimonopoly Commission last year ruled that Bryntsalov violated trademark of Danish insulin maker Novo Nordisk. BROKEN CONTRACTS Moscow Arbitration Court last year ruled Bryntsalov sold Russian Ministry of Health animal insulin instead of more expensive human gene-engineered insulin, as called for in contract. COUNTERFEITING French pharmaceutical giant Aventis suspects Bryntsalov of counterfeiting Claforan, the leading antibiotic sold in Russia. SUPPLIER COMPLAINTS Netherlands-based insulin crystal maker Diosynth terminated supplies to Bryntsalov over concerns that he used their crystals in formula before receiving regulatory approval. UNPAID DEBTS Novo Nordisk preparing suit against Bryntsalov in international arbitration court in Geneva for nonpayment of $6.5 million debt. Data: Court Documents, BusinessWeek _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ BACK TO TOP					RELATED ITEMS The Trials of a Russian Drug Czar (int'l edition) TABLE: Russia's Rogue Pharmaceuticals Tycoon TABLE: Hot Water for Bryntsalov INTERACT E-Mail to Business Week Online

Copyright 2000-2009, by The McGraw-Hill Companies Inc. All rights reserved. Terms of Use   Privacy Notice